CA2342432A1 - Compose nouveau - Google Patents

Compose nouveau Download PDF

Info

Publication number
CA2342432A1
CA2342432A1 CA002342432A CA2342432A CA2342432A1 CA 2342432 A1 CA2342432 A1 CA 2342432A1 CA 002342432 A CA002342432 A CA 002342432A CA 2342432 A CA2342432 A CA 2342432A CA 2342432 A1 CA2342432 A1 CA 2342432A1
Authority
CA
Canada
Prior art keywords
disorders
salt
free base
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002342432A
Other languages
English (en)
Inventor
Christopher Norbert Johnson
Brian E. Burpitt
Andrew Colin Share
Geoffrey Stemp
Gregor James Macdonald
Inderjit Singh Mann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to CA002342432A priority Critical patent/CA2342432A1/fr
Publication of CA2342432A1 publication Critical patent/CA2342432A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002342432A 2001-03-28 2001-03-28 Compose nouveau Abandoned CA2342432A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002342432A CA2342432A1 (fr) 2001-03-28 2001-03-28 Compose nouveau

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002342432A CA2342432A1 (fr) 2001-03-28 2001-03-28 Compose nouveau

Publications (1)

Publication Number Publication Date
CA2342432A1 true CA2342432A1 (fr) 2002-09-28

Family

ID=4168721

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002342432A Abandoned CA2342432A1 (fr) 2001-03-28 2001-03-28 Compose nouveau

Country Status (1)

Country Link
CA (1) CA2342432A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1725240A1 (fr) * 2004-03-17 2006-11-29 Glaxo Group Limited Antagonistes du recepteur d'acetylcholine muscarinique
EP1725241A1 (fr) * 2004-03-17 2006-11-29 Glaxo Group Limited Antagonistes du recepteur d'acetylcholine muscarinique m3
US8486982B2 (en) 2003-04-11 2013-07-16 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acids
US20140100247A1 (en) * 2011-05-19 2014-04-10 Bruce Roseman Method of treating apraxia of speech in children
US9220712B2 (en) 2011-05-19 2015-12-29 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention and method for treating an apraxia of speech in children
US9307942B2 (en) 2011-05-19 2016-04-12 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy gait impairment
US9375421B2 (en) 2011-05-19 2016-06-28 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention for treating an apraxia of speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
CN110498768A (zh) * 2018-05-17 2019-11-26 上海中泽医药科技有限公司 庚嗪类化合物及其在制备抗精神分裂症药物中的应用
US10517853B2 (en) 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11578084B2 (en) 2018-01-26 2023-02-14 Shionogi & Co., Ltd. Condensed ring compounds having dopamine D3 receptor antagonistic effect

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486982B2 (en) 2003-04-11 2013-07-16 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acids
US10071081B2 (en) 2003-04-11 2018-09-11 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use
US8796322B2 (en) 2003-04-11 2014-08-05 Ptc Therapeutics, Inc. Methods for using 1,2,4-oxadiazole benzoic acid compounds
US8975287B2 (en) 2003-04-11 2015-03-10 Ptc Therapeutics, Inc. Methods for using 1,2,4-Oxadiazole benzoic acid compounds
US9861617B2 (en) 2003-04-11 2018-01-09 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use
US9205088B2 (en) 2003-04-11 2015-12-08 Ptc Therapeutics, Inc. Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use
EP1725240A1 (fr) * 2004-03-17 2006-11-29 Glaxo Group Limited Antagonistes du recepteur d'acetylcholine muscarinique
EP1725241A1 (fr) * 2004-03-17 2006-11-29 Glaxo Group Limited Antagonistes du recepteur d'acetylcholine muscarinique m3
EP1725240A4 (fr) * 2004-03-17 2009-03-25 Glaxo Group Ltd Antagonistes du recepteur d'acetylcholine muscarinique
EP1725241A4 (fr) * 2004-03-17 2009-03-25 Glaxo Group Ltd Antagonistes du recepteur d'acetylcholine muscarinique m3
US9408838B2 (en) 2011-05-19 2016-08-09 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy gait impairment
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
US9333198B2 (en) 2011-05-19 2016-05-10 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy gait impairment
US9375421B2 (en) 2011-05-19 2016-06-28 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention for treating an apraxia of speech in children
US9220712B2 (en) 2011-05-19 2015-12-29 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention and method for treating an apraxia of speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US9089563B2 (en) * 2011-05-19 2015-07-28 Gilrose Pharmaceuticals, Llc Method of treating apraxia of speech in children
US10834891B2 (en) 2011-05-19 2020-11-17 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech gait and limb impairments treatment
US20140100247A1 (en) * 2011-05-19 2014-04-10 Bruce Roseman Method of treating apraxia of speech in children
US9307942B2 (en) 2011-05-19 2016-04-12 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy gait impairment
US10420318B2 (en) 2011-05-19 2019-09-24 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
US10233161B2 (en) 2014-03-06 2019-03-19 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10618877B2 (en) 2014-03-06 2020-04-14 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US9873677B2 (en) 2014-03-06 2018-01-23 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
US10517853B2 (en) 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11345716B2 (en) 2016-07-28 2022-05-31 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11897899B2 (en) 2016-07-28 2024-02-13 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11578084B2 (en) 2018-01-26 2023-02-14 Shionogi & Co., Ltd. Condensed ring compounds having dopamine D3 receptor antagonistic effect
CN110498768A (zh) * 2018-05-17 2019-11-26 上海中泽医药科技有限公司 庚嗪类化合物及其在制备抗精神分裂症药物中的应用

Similar Documents

Publication Publication Date Title
JP3507494B2 (ja) タキキニン拮抗薬
JP4272423B2 (ja) ドーパミンｄ３受容体のモジュレーターとして有用なテトラヒドロベンズアゼピン誘導体（抗精神病剤）
JP4488891B2 (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
US6605607B1 (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
SA98190402B1 (ar) تركيب متعدد الشكل البللوري لمضاد مستقبل التاكيكين
CA2342432A1 (fr) Compose nouveau
US9611224B2 (en) Antiproliferative benzo [B] azepin-2-ones
TWI360540B (en) Tetrahydroisoquinolylsulphonamide derivatives, the
CZ203593A3 (en) Quaternary basic amides, process of their preparation and pharmaceutical preparations based thereon
CA2180238A1 (fr) Nouveaux composes heterocycliques
BG64703B1 (bg) Полиморфна форма на 2-(r)-(1-(r)-(3,5-бис(трифлуорометил) фенил)етокси)-3-(s)-(4-флуоро)-фенил-4-(3-(5-оксо-1н,4н- 1,2,4-триазоло)метилморфолин, метод за нейното получаване и фармацевтични състави, които я съдържат
JP2001522366A (ja) ドーパミンｄ▲上３▼受容体のモジュレーターとしての置換テトラヒドロイソキノリン誘導体
TW321640B (fr)
PT93218B (pt) Processo para a preparacao de 2-amino-1,2,3,4-tetra-idronaftalenos e 3-aminocromanos substituidos no anel
JPS60255770A (ja) 新規ベンゾアゼピン誘導体
JP4694747B2 (ja) 二環式バソプレッシン・アゴニスト
US6521638B1 (en) 2,3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6358974B1 (en) Isoquinoline derivatives
CN101506156A (zh) 对GlyT1转运蛋白具有活性的吡咯烷衍生物
WO2000049017A1 (fr) Dioxydes de 1-((indoly azacycloalkyl) alkyl)-2,1, 3-benzothiadiazole 2,2 faisant montre d'une activite de recepteur 5-ht2a
EP1086095B1 (fr) Derives de tetrahydroisoquinoleine utilises comme modulateurs des recepteurs d 3 de la dopamine
TW419478B (en) 6-methoxy-1H-benzotriazol-5-carboxamide derivatives, preparation and pharmaceutical composition
US6855717B2 (en) Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
JPH04225954A (ja) アミド化合物、その医薬用途および新規１−置換ピロリジンメチルアミン類
MXPA01003645A (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)

Legal Events

Date Code Title Description
FZDE Dead